Paying for value with few incentives vexes health care companies

WASHINGTON — Pharmaceutical company Johnson & Johnson (JNJ) and insurance giant Aetna (AET) are partnering on “value-based” contracts for diabetes care, a practice executives from the companies discussed during an industry breakfast Tuesday morning.

J&J executive vice president Joaquin Duato said that one of the agreements covers the type 2 diabetes drug Invokana. J&J gives Aetna a rebate if a predetermined percentage of patients have to take additional diabetes medications.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It’s easy! Your first 30 days are free and if you don’t enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.


Please enter your comment!
Please enter your name here

one + eleven =